Aptevo Therapeutics Inc [NASDAQ: APVO] surged by $0.06 during the normal trading session on Tuesday and reaching a high of $2.71 during the day while it closed the day at $1.5.
Aptevo Therapeutics Inc stock has also loss -1.96% of its value over the past 7 days. However, APVO stock has declined by -59.02% in the 3 months of the year. Over the past six months meanwhile, it has lost -97.16% and lost -99.44% year-on date.
The market cap for APVO stock reached $4.93 million, with 3.22 million shares outstanding and 3.00 million shares in the current float. Compared to the average trading volume of 2.24M shares, APVO reached a trading volume of 113866291 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Aptevo Therapeutics Inc [APVO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for APVO shares is $21.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on APVO stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ladenburg Thalmann have made an estimate for Aptevo Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 05, 2018. While these analysts kept the previous recommendation, Piper Jaffray raised their target price to Overweight. The new note on the price target was released on October 05, 2017, representing the official price target for Aptevo Therapeutics Inc stock.
The Price to Book ratio for the last quarter was 0.74, with the Price to Cash per share for the same quarter was set at 2.86.
APVO stock trade performance evaluation
Aptevo Therapeutics Inc [APVO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.96. With this latest performance, APVO shares dropped by -25.00% in over the last four-week period, additionally sinking by -97.16% over the last 6 months – not to mention a drop of -98.26% in the past year of trading.
Aptevo Therapeutics Inc (APVO) Capital Structure & Debt Analysis
According to recent financial data for Aptevo Therapeutics Inc. ( APVO), the Return on Equity (ROE) stands at -437.34%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -157.31%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Aptevo Therapeutics Inc’s Return on Invested Capital (ROIC) is -223.84%, showcasing its effectiveness in deploying capital for earnings.
Aptevo Therapeutics Inc (APVO) Efficiency & Liquidity Metrics
Based on Aptevo Therapeutics Inc’s (APVO) latest financial statements, the Debt-to-Equity Ratio is 0.65%, indicating its reliance on debt financing relative to shareholder equity.
Aptevo Therapeutics Inc (APVO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Aptevo Therapeutics Inc. (APVO) effectively leverages its workforce, generating an average of -$571904.76 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.27% and a Quick Ratio of 2.27%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Aptevo Therapeutics Inc [APVO] stock
With the latest financial reports released by the company, Aptevo Therapeutics Inc posted -355.2/share EPS, while the average EPS was predicted by analysts to be reported at -421.8/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 66.6. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for APVO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Aptevo Therapeutics Inc go to 83.99%.
Aptevo Therapeutics Inc [APVO]: Institutional Ownership
There are presently around $0.47%, or 0.47%% of APVO stock, in the hands of institutional investors.
